NAMRL-1152

THE EFFECTIVENESS OF BENACTYZINE HYDROCHLORIDE AND OTHER ANTIMOTION SICKNESS DRUGS IN NEW COMBINATIONS

Charles D. Wood and Ashton Graybiel





NATIONAL TECHNICAL INFORMATION SERVICE Springfield, Va. 22151

December 1971



Approved for public release; distribution unlimited.

W

9

THE EFFECTIVENESS OF BENACTYZINE HYDROCHLORIDE AND OTHER ANTIMOTION SICKNESS DRUGS IN NEW COMBINATIONS

Charles D. Wood and Ashton Graybiel

Bureau of Medicine and Surgery MF12 524.005-7015BX8X

Released by

Captain N. W. Allebach, MC USN Officer in Charge

6 December 1971

Naval Aerospace Medical Research Laboratory
Naval Aerospace Medical Institute
Naval Aerospace Medical Center
Pensacola, Florida 32512

SUMMARY PAGE

THE PROBLEM

To compare the effectiveness of five different drug preparations in preventing motion sickness with that found for the combination of scopolamine 0.6 mg with damphetamine 10 mg in previous studies.

FINDINGS

Promethazine 25 mg plus d-amphetamine 10 mg was essentially equal to the baseline drug in range of effectiveness. Halving the doses of the baseline combination did not provide the protection it did in an earlier study. Benactyzine 3 mg was only slightly effective and when combined with d-amphetamine 10 mg was only moderately so. Promethazine 25 mg plus ephedrine 25 mg was about one-fourth less effective than the baseline preparation. The unexpected finding of the efficacy of small doses (25 mg) of promethazine plus ephedrine is pointed out, and the benefits from the relatively great reduction in side effects found with this drug combination are stressed.

| 1 | Inc | lassi | ified |
|---|-----|-------|-------|
| | | | |

| والمتناز والمناز والمن | ndexing annotation t | A - R&D | ne overall report is classified) |
|--|--|---|--|
| ORIGINATING ACTIVITY (Corporate author) | | 20. REPORT | SECURITY CLASSIFICATION |
| Naval Aerospace Medical Research Labo | pratory | 26. GROUP | classified |
| Pensacola, Florida 32512 | | N, | / <u>A</u> |
| THE EFFECTIVENESS OF BENACTYZIN SICKNESS DRUGS IN NEW COMBINA | | ORIDE AND O | THER ANTIMOTION |
| DESCRIPTIVE NOTES (Type of report and inclusive dates) | | | |
| Charles D. Wood and Ashton Graybiel | | | |
| 6 December 1971 | 78. TOTA | NO. OPPAGES | 76, NO. OF REFS |
| CONTRACT OR GR NT NO. | 94. ORIGI | NATOR'S REPORT NO | |
| PROJECT NO. BuMed MF12.524.005-7015BX8X | | NAMRL-1152 | |
| | 9b. OTHE | | other numbers that may be assigned |
| SUPPLEMENTARY NOTES | 12. SPON | ORING MILITARY AC | TIVITY |
| | · I | | |
| N/A ABSTRACT | | N/A | |
| Five different drug preparations are consickness with the effectiveness found for the mine 10 mg in previous studies. Promethat equal to the baseline drug in range of effetion did not provide the protection that it slightly effective and when combined with thatine 25 mg plus ephedrine 25 mg was altion. The unexpected finding of the effict drine is pointed out, and the benefits from | ne combination zine 25 mg plu ctiveness. Ha did in an earl d-amphetami bout one-fourt acy of small d | eir effectivenes of scopolamine is d-amphetamin living the doses ier study. Bena ne 10 mg was or h less effective oses (25 mg) of | 0.6 mg with d-ampheta ie 10 mg was essentially of the baseline combina- ctyzine 3 mg was only ily moderately so. Prom than the baseline prepai promethazine plus ephe- |
| ABSTRACT | ne combination zine 25 mg plu ctiveness. Ha did in an earl d-amphetami bout one-fourt acy of small d | eir effectivenes of scopolamine is d-amphetamin living the doses ier study. Bena ne 10 mg was or h less effective oses (25 mg) of y great reduction | 0.6 mg with d-amphete ie 10 mg was essentially of the baseline combine ctyzine 3 mg was only ily moderately so. Pron than the baseline prepa promethazine plus ephe- |

Unclassified

| Security Classification | | | | | | | | |
|-----------------------------------|-----------|-------------|----------|------------|----------|----------|-----|--|
| 14. | | LINK A LINK | | | K 9 | B LINK C | | |
| | KEY WORDS | ROLE | WT | ROLE | WT | ROLE | WT | |
| | | | | | | | | |
| | | 1 | | | | | | |
| Motion sickness prevent | ion | ì ' | | | 1] | | | |
| Tribiton dicitalization provident | | | | | 1 1 | - | | |
| | | Ì ' | | | i | | | |
| Corio!is acceleration | | | 1 | | i | | | |
| | | | | | 1 | | | |
| 01 | at almoss | } | | | 1 | | | |
| Pharmacology in motion | sickness | | 1 | | 1 | | | |
| | | | | | 1 | | | |
| | | ! | | | | | | |
| | |] | | | | | | |
| | | 1 | | | 1 | | | |
| | | | | | | | | |
| | • | l | • | | 1 1 | | | |
| | | | | | 1 | | | |
| | | 1 | | ' | 1 | | | |
| | | | | | | | | |
| | |] |] | · ' | ! | | | |
| | | l | | Ī | | | | |
| | | 1 | | | | | | |
| | | ļ | | | 1 | | | |
| | | 1 | | | | | | |
| | | 1 | 1 | | | | | |
| | | | | | 1 | | | |
| | | <u> </u> | 1 | | | | | |
| | | į. | ļ | | | | | |
| | | i | | | | | | |
| | | ł | , | | | | | |
| | | ļ | | 1 | 1 | | | |
| | | ì | | | 1 | | | |
| | | |] | | i I | | | |
| | | 1 |] | · | | | | |
| | | | ļ | | | | | |
| | | 3 | 1 | l . | 1 | | | |
| | | 1 | | 1 | <u> </u> | | | |
| | | j | | | 1 1 | | | |
| | | i | Ì ' | · | | | | |
| | | | Į I | | į : | | | |
| | | 1 | | | i l | | | |
| | | • |] | | 1 | | | |
| | | ľ | i i | | 1 | | í | |
| | | 1 | | | 1 | | | |
| i | | i | | | 1 | | | |
| | | Ì | l | | 1 1 | 1 | | |
| | | l | | | 1 | | | |
| | | Ī | 1 | | 1 | l I | | |
| | | 5 | 1 | | 1 | 1 | | |
| | | Í | 1 | | 1 | | | |
| | | ì | 1 | | i | | | |
| | | ł | Į į | | 1 | | l i | |
| | | l |] | | [| | | |
| | | ļ | • | | 1 | İ | | |
| | | 1 | | | 1 | | i l | |
| | | ì | 1 | | 1 | | | |
| | | | | | 1 | |]] | |
| | | 1 |] | | 1 | | | |
| | | Į . | į į | | 1 | [| | |
| | | 1 | [| | 1 | | | |
| | | 1 | | | | | | |
| | | | | | | | i | |
| 1 | | j | | | | | | |
| | | l | | l | | | İ | |
| | | Ì | 1 | | | | | |
| | | 1 | | | | | | |
| | | | | | 4 | | | |

DD . mov .. 1473 (FACK)

Unclassified
Security Classification

INTRODUCTION

In previous studies it was found that the combination of scopolamine hydrobromide with d-amphetamine sulfate was the most effective preparation for prevention of motion sickness, and this led to its being used as a "standard" for comparing the effectiveness of other drugs with parasympatholytic or sympathomimetic action. In this study we investigated the effectiveness of benactyzine hydrochloride and of combinations of other antimotion sickness drugs based on this standard.

PROCEDURE

The subjects were 10 healthy men, 18 to 21 years of age, who demonstrated normal responses in tests designed to measure the functional integrity of the otolithic and canalicular receptor systems of the inner ear. Euch subject was rotated on a slow rotation room (SRR) and his susceptibility to motion sickness determined by means of the Dial Test (1). This test consists of setting the pointer on each of five dials arranged around the subject in such a manner as to require him to make five different head-body movements out of the plane of the room's rotation, generating the stressful accelerations. The head movements are paced by a tape recording that gives numbers to be set on the dials in randomized order at a rate of one every 6 seconds. The velocity (rpm) of the SRR at which severe malaise (M III) (2) was elicited during the execution of less than 50 head movements served as a subject's "control" susceptibility level. This speed of rotation was then maintained for that subject during subsequent experimental trials. Severe malaise, although a mild level of motion sickness, is of demonstrably high reliability as an endpoint under the circumstances of the present experiment.

Five different drug preparations, three of which were combined with others and one used alone, along with two placebos were administered according to a modified ten-unit Latin square design.

The drugs and placebos were placed in identical opaque gelatin capsules, and the double-blind technique of administration was used. A baseline was drawn by using the control and placebo values, and the change (increase) in number of head movements above the baseline was used to indicate the effectiveness of a drug or drug combination.


Drug Preparations:

| scopolamine hydrobromide plus | 0.3 | 3 mg |
|------------------------------------|-----|------|
| d-amphetamine sulfate | 5 | mg |
| benactyzine hydrochloride | 3 | mg |
| benactyzine hydrochloride plus | 3 | mg |
| d-amphetamine sulfate | 10 | mg |
| promethazine hydrochloride plus | 25 | mg |
| d-amphetamine sulfate | 10 | mg |
| scopolamine hydrobromide plus | 0.6 | 5 mg |
| d-amphetamine sulfate | 10 | mg |
| promethazine hydrochloride plus | 25 | mg |
| ophedrine sulfate | 25 | mg |

RESULTS AND DISCUSSION

The results are summarized in Figure 1. The combination of scopolamine 0.6 mg with d-amphetamine 10 mg was (again) the most effective preparation tested. The increase in number of "tolerated" head movements with this combination of drugs was about the same as that reported previously, although the combination of scopolamine 0.3 mg with d-amphetamine 5 mg was found to be less effective than previously reported (3). Benactyzine in the 3-mg dose was only slightly effective under the conditions of this study. Moreover, in combination with d-amphetamine 10 mg it was only moderately effective, and it is doubtful, based on past experience with d-amphetamine (3), if the beneficial effects of the two drugs summated. Promethazine 25 mg combined with d-amphetamine 10 mg was found to be nearly as effective as when it was combined with scopolamine 0.6 mg, confirming earlier findings (4).

The unexpected finding was the efficacy of small doses (25 mg) of promethazine and ephedrine in combination. The 25 per cent reduction in effectiveness of that combination compared with the best combination, if confirmed, is more than compensated by the relatively great reduction in side effects. Moreover, this level of effectiveness is above that demonstrated (5) for many of the drugs used to prevent motion sickness under conditions of commercial travel, and repeated doses are not contraindicated.



Effectiveness of each drug tested in terms of average increase above placeluo level (zero line) in tolerated head movements.

REFERENCES

- Kennedy, R. S., and Graybiel, A., The Dial Test: A standardized procedure for for the experimental production of canal sickness symptomatology in a rotating environment. NSAM-930. Pensacola, Fla.: Naval School of Aviation Medicine, 1965.
- 2. Graybiel, A., Wood, C. D., Miller, E. F. II, and Cramer, D. B., Diagnostic criteria for grading the severity of acute motion sickness. <u>Aerospace Med.</u>, 39:453-455, 1963.
- 3. Wood, C. D., and Graybiel, A., Evaluation of sixteen antimotion sickness drugs under controlled laboratory conditions. <u>Aerospace Med.</u>, <u>39</u>:1342-1344, 1968.
- 4. Wood, C. D., and Graybiel, A., Evaluation of antimotion sickness drugs: A new effective remedy revealed. <u>Aerospace Med., 41</u>:932–933, 1970.
- 5. Wood, C. D., Kennedy, R. S., Graybiel, A., Trumbull, R., and Wherry, R. J., Jr., Clinical effectiveness of antimotion sickness drugs. J. Amer. Med. Ass., 198: 1155–1158, 1966.